| scholarly article | Q13442814 |
| P356 | DOI | 10.1148/RADIOL.12111148 |
| P698 | PubMed publication ID | 22692034 |
| P2093 | author name string | Wu-Chou Su | |
| Helen H W Chen | |||
| How-Ran Guo | |||
| Bi-Fang Lee | |||
| Nan-Tsing Chiu | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography | Q130273251 |
| lung cancer | Q47912 | ||
| P1104 | number of pages | 8 | |
| P304 | page(s) | 559-566 | |
| P577 | publication date | 2012-06-12 | |
| P1433 | published in | Radiology | Q3285690 |
| P1476 | title | Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer | |
| P478 | volume | 264 |
| Q33904549 | 18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response |
| Q90353138 | A 18FDG PET/CT-based volume parameter is a predictor of overall survival in patients with local advanced gastric cancer |
| Q35688617 | A new PET/CT volumetric prognostic index for non-small cell lung cancer |
| Q36951545 | A novel metric for quantification of homogeneous and heterogeneous tumors in PET for enhanced clinical outcome prediction |
| Q34097425 | A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. |
| Q27025770 | Advanced imaging (positron emission tomography and magnetic resonance imaging) and image-guided biopsy in initial staging and monitoring of therapy of lung cancer |
| Q45954854 | Amplitude-based optimal respiratory gating in positron emission tomography in patients with primary lung cancer. |
| Q38934437 | Application of novel quantitative techniques for fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer |
| Q41026685 | Assessment of Mediastinal Tumors Using SUVmax and Volumetric Parameters on FDG-PET/CT. |
| Q36769240 | Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study |
| Q40872263 | Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer. |
| Q36304366 | Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times |
| Q40888969 | Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment? |
| Q49386829 | Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better? |
| Q91386320 | Deep segmentation networks predict survival of non-small cell lung cancer |
| Q37261280 | Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT. |
| Q44435039 | Do clinical characteristics and metabolic markers detected on positron emission tomography/computerized tomography associate with persistent disease in patients with in-operable cervical cancer? |
| Q53074113 | Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential ¹⁸F-FDG PET/CT and MRI. |
| Q38641099 | Emerging Role of MRI for Radiation Treatment Planning in Lung Cancer |
| Q37425433 | FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies |
| Q53089675 | FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma. |
| Q57152907 | FDG-PET imaging to detect and characterize underlying causes of fever of unknown origin: an unavoidable path for the foreseeable future |
| Q92457848 | FDG-PET parameters predict for recurrence in anal cancer - results from a prospective, multicentre clinical trial |
| Q37193816 | Incorporating prognostic imaging biomarkers into clinical practice |
| Q33648454 | LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma |
| Q57471881 | Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA (ctDNA) in metastatic melanoma |
| Q42532688 | Measuring total liver function on sulfur colloid SPECT/CT for improved risk stratification and outcome prediction of hepatocellular carcinoma patients |
| Q47735250 | Metabolic tumor burden quantified on [18F]FDG PET/CT improves TNM staging of lung cancer patients |
| Q91190916 | Metabolic tumor volume and total lesion glycolysis predict tumor progression and survival after salvage surgery for recurrent oral cavity squamous cell carcinoma |
| Q39373649 | Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235. |
| Q91584793 | Metabolic tumor volume predicts overall survival in patients with primary pulmonary lymphoepithelioma-like carcinoma |
| Q39330511 | Molecular image-directed biopsies: improving clinical biopsy selection in patients with multiple tumors |
| Q38660859 | Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. |
| Q60302572 | Optimization of PET reconstruction algorithm, SUV thresholding algorithm and PET acquisition time in clinical 11C-acetate PET/CT |
| Q38444980 | PET in the management of locally advanced and metastatic NSCLC. |
| Q42721856 | PET quantification with a histogram derived total activity metric: superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients |
| Q33814606 | PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST). |
| Q38202189 | PET/CT in therapy evaluation of patients with lung cancer |
| Q53095046 | Prediction for recurrence using F-18 FDG PET/CT in pathologic N0 lung adenocarcinoma after curative surgery. |
| Q42664426 | Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing (18)F-FDG PET/CT SUV quantification |
| Q37026232 | Prediction of Central Nervous System Relapse of Diffuse Large B-Cell Lymphoma Using Pretherapeutic [18F]2-Fluoro-2-Deoxyglucose (FDG) Positron Emission Tomography/Computed Tomography |
| Q47856252 | Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer |
| Q37227687 | Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial |
| Q38819166 | Present and future roles of FDG-PET/CT imaging in the management of lung cancer. |
| Q35474006 | Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235. |
| Q35582133 | Prognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer. |
| Q36060090 | Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status |
| Q34113079 | Prognostic Value of Fluoro-D-glucose Uptake of Primary Tumor and Metastatic Lesions in Advanced Nonsmall Cell Lung Cancer |
| Q50211377 | Prognostic Value of Tumor-to-Blood Standardized Uptake Ratio in Patients with Resectable Non-Small-Cell Lung Cancer. |
| Q53125167 | Prognostic implications of volume-based measurements on FDG PET/CT in stage III non-small-cell lung cancer after induction chemotherapy. |
| Q55155523 | Prognostic significance of combined radiologic imaging modalities for prognosis of clinical IA adenocarcinomas. |
| Q44216158 | Prognostic significance of preoperative metabolic tumour volume and total lesion glycolysis measured by (18)F-FDG PET/CT in squamous cell carcinoma of the oral cavity |
| Q53003832 | Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma. |
| Q90446293 | Prognostic value of metabolic parameters measured by 18F-fluorodeoxyglucose positron emission tomography-computed tomography in surgically resected non-small cell lung cancer patients |
| Q37413672 | Prognostic value of metabolic tumor burden in lung cancer |
| Q59326906 | Prognostic value of metabolic tumor volume of pretreatment F-FAMT PET/CT in non-small cell lung Cancer |
| Q90655978 | Prognostic value of post-induction chemotherapy 18F-FDG PET-CT in stage II/III non-small cell lung cancer before (chemo-) radiation |
| Q53063987 | Prognostic value of pretreatment 18F-fluorodeoxyglucose positron emission tomography/CT volume-based parameters in patients with oropharyngeal squamous cell carcinoma with known p16 and p53 status. |
| Q39127172 | Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer |
| Q37482604 | Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. |
| Q38417118 | Prognostic value of total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with uterine carcinosarcoma |
| Q48241629 | Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients |
| Q38246442 | Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis |
| Q53090438 | Quantitative assessment of global hepatic glycolysis in patients with cirrhosis and normal controls using 18F-FDG-PET/CT: a pilot study. |
| Q33669828 | Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology. |
| Q46506999 | Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers |
| Q35637414 | Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images |
| Q64234207 | Repeatability of [F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients |
| Q36093008 | Reproducibility and uptake time dependency of volume-based parameters on FDG-PET for lung cancer |
| Q35940876 | Respiration-Averaged CT for Attenuation Correction of PET Images - Impact on PET Texture Features in Non-Small Cell Lung Cancer Patients |
| Q38925887 | Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer |
| Q57116080 | Simultaneous characterization of tumor cellularity and the Warburg effect with PET, MRI and hyperpolarized C-MRSI |
| Q90048709 | Solitary Pulmonary Nodule: Morphological Effects on Metabolic Activity Assessment |
| Q37507351 | The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC. |
| Q45952058 | The increment in standardized uptake value determined using dual-phase 18F-FDG PET is a promising prognostic factor in non-small-cell lung cancer. |
| Q38715401 | The role of PET/CT as a prognosticator and outcome predictor in lung cancer |
| Q33779663 | The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer |
| Q36461563 | Total Lesion Glycolysis Using ¹⁸F-FDG PET/CT as a Prognostic Factor for Locally Advanced Esophageal Cancer |
| Q45917673 | Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma. |
| Q53327726 | Total lesion glycolysis by 18F-FDG PET/CT is independent prognostic factor in patients with advanced non-small cell lung cancer. |
| Q41660750 | Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation. |
| Q87877317 | Utilization of a hybrid finite-element based registration method to quantify heterogeneous tumor response for adaptive treatment for lung cancer patients |
| Q87928043 | Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma |
| Q53063872 | Variability of average SUV from several hottest voxels is lower than that of SUVmax and SUVpeak. |
| Q55195416 | Volume of interest delineation techniques for 18F-FDG PET-CT scans during neoadjuvant extremity soft tissue sarcoma treatment in adults: a feasibility study. |
| Q45247422 | Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer |
| Q34468661 | Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer |
Search more.